Structure-based ligand design and the promise held for antiprotozoan drug discovery

    Research output: Contribution to journalReview article

    40 Citations (Scopus)

    Abstract

    The development of the pharmaceutical industry, driven by progress in chemistry, biology, and technology, ranks as one of the most successful of human endeavors. However, serious health problems persist, among which are diseases caused by protozoan parasites, largely ignored in modern times. Advances in genomic sciences, molecular and structural biology, and computational and medicinal chemistry now set the scene for a renewed assault on such infections. A structure-centric approach to support discovery of antiparasitic compounds promises much. Current strategies and benefits of a structure-based approach to support early stage drug discovery will be described.

    Original languageEnglish
    Pages (from-to)11749-11753
    Number of pages5
    JournalJournal of Biological Chemistry
    Volume284
    Issue number18
    DOIs
    Publication statusPublished - 1 May 2009

    Keywords

    • PLASMODIUM-FALCIPARUM
    • NATURAL-PRODUCTS
    • TARGETS
    • DISEASES
    • LEISHMANIASIS
    • DRUGGABILITY
    • TRYPANOSOMA
    • LIBRARIES
    • BIOLOGY
    • TRENDS

    Cite this